Latacris

Latanoprost, the active ingredient in Latacris, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intraocular pressure and is employed in the management of glaucoma and ocular hypertension in adult patients. The medication is indicated for primary open‑angle glaucoma and for patients with elevated eye pressure who are at risk of optic nerve damage.

GNH USA supplies Latacris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under strict quality controls.

Latanoprost, marketed as Latacris, acts on the prostaglandin pathway to reduce intraocular pressure in glaucoma‑related conditions.

Primary open-angle glaucoma: reduces intraocular pressure to help preserve visual field. Ocular hypertension: lowers eye pressure to prevent progression to glaucoma. Secondary open-angle glaucoma: decreases intraocular pressure in cases where glaucoma develops secondary to other ocular conditions.

Latanoprost may cause ocular and systemic reactions; most are mild, but some require medical attention.

Common Side Effects: - Eye redness (hyperemia). - Increased iris pigmentation. - Eyelash growth and darkening. - Eye irritation or foreign‑body sensation. - Blurred vision.

Serious or Rare Side Effects: - Uveitis or intraocular inflammation. - Macular edema leading to visual disturbance. - Severe allergic reaction such as angio‑edema or anaphylaxis. - Persistent eye pain. - Sudden loss of vision.

Before initiating therapy, clinicians should consider several safety measures.

Baseline IOP measurement: assess intraocular pressure before starting therapy. Monitor iris color: watch for progressive darkening of the iris. Avoid in active ocular inflammation: contraindicated in uveitis or other intraocular inflammatory conditions. Hypersensitivity: discontinue if an allergic reaction occurs. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analog eye drops: may cause excessive intraocular pressure reduction. - Combination with ocular corticosteroids: may diminish the therapeutic effect of latanoprost.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Systemic beta‑blockers: additive hypotensive effect is generally minimal but blood pressure should be monitored. - Anticholinergic agents: may affect pupil size and ocular dynamics.